Bulk Pharmaceutical API Sources for acamprosate calcium

Bulk Pharmaceutical API Sources for acamprosate calcium

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-003-666-799
Hangzhou APIChem Technology		AC-5599
TCI (Tokyo Chemical Industry)		A2359
Amadis Chemical		A839056
AKos Consulting & Solutions		AKOS015895192

ACAMPROSATE CALCIUM Bulk Active Pharmaceutical Ingredient (API) Sources

Last updated: February 19, 2026

This report identifies key manufacturers and suppliers of Acamprosate Calcium bulk API, providing critical data for R&D and investment decisions. The analysis focuses on supplier capabilities, geographic distribution, regulatory compliance, and market presence.

Who are the Primary Global Manufacturers of Acamprosate Calcium API?

The global supply of Acamprosate Calcium API is concentrated among a limited number of manufacturers, primarily located in India and China. These companies operate at scale, meeting the demand for both generic and branded pharmaceutical formulations.

• Active Pharmaceutical Ingredient (API) Manufacturers:
  • Strides Pharma Science Limited (India): A significant producer with established manufacturing facilities.
  • Laurus Labs Limited (India): Known for its broad API portfolio and robust R&D capabilities.
  • Alkem Laboratories Ltd. (India): A major Indian pharmaceutical company with substantial API manufacturing capacity.
  • Divi's Laboratories Limited (India): A prominent supplier of APIs and intermediates globally.
  • Sun Pharmaceutical Industries Ltd. (India): One of the largest pharmaceutical companies worldwide, with integrated API production.
  • Zydus Lifesciences Limited (India): Formerly Cadila Healthcare, a diversified group with API manufacturing operations.
  • Jiangsu Hengdian Group Biomedical Co., Ltd. (China): A key Chinese player in the pharmaceutical ingredient sector.
  • Anspec Company, Inc. (USA): While primarily a distributor and custom synthesis provider, Anspec offers Acamprosate Calcium API sourced from global manufacturers for the North American market.

These companies have developed specialized processes for Acamprosate Calcium synthesis, aiming for high purity and consistent quality to meet stringent pharmacopeial standards.

What are the Key Manufacturing Locations and Their Impact on Supply Chain?

The geographic concentration of Acamprosate Calcium API manufacturing in India and China significantly influences global supply chain dynamics, including cost, lead times, and regulatory oversight.

• Dominant Manufacturing Hubs:

  • India: Holds a substantial share of global API production due to its established pharmaceutical infrastructure, skilled workforce, and cost-competitive manufacturing. Indian manufacturers are major suppliers to regulated markets like the U.S. and Europe.
  • China: Also a major API producer, China contributes significantly to the global supply. Chinese manufacturers often compete on price and volume, though quality and regulatory compliance are increasingly scrutinized by international bodies.

• Supply Chain Considerations:

  • Logistics and Lead Times: Shipments from these regions to North America and Europe involve considerable transit times, necessitating robust inventory management and forecasting by pharmaceutical formulators.
  • Regulatory Compliance: Manufacturers must adhere to Good Manufacturing Practices (GMP) as defined by regulatory agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others. Facilities are subject to inspections by these bodies.
  • Geopolitical Factors: Trade policies, tariffs, and global events can impact the stability and cost of APIs sourced from these regions. Diversification of sourcing is a strategy employed by some companies to mitigate these risks.

What Regulatory Approvals and Quality Standards are Essential for Acamprosate Calcium API Suppliers?

Suppliers of Acamprosate Calcium API must demonstrate compliance with a rigorous set of regulatory requirements and quality standards to be eligible for use in pharmaceutical products.

• Key Regulatory Filings and Certifications:

  • Drug Master Files (DMFs): U.S. DMFs provide detailed information about the manufacturing process, facilities, and controls for an API to the FDA. European Active Substance Master Files (ASMFs) serve a similar purpose in Europe.
  • Certificates of Suitability (CEP): Issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM), a CEP certifies that an API complies with the requirements of the European Pharmacopoeia.
  • GMP Compliance: Adherence to current Good Manufacturing Practices (cGMP) as defined by regulatory bodies like the FDA is mandatory. This includes validation of manufacturing processes, quality control testing, and robust quality management systems.
  • Pharmacopeial Standards: APIs must meet the purity and quality specifications outlined in major pharmacopeias, including the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP).
  • Site Registrations and Inspections: Manufacturing sites are subject to routine inspections by regulatory authorities. Successful inspection outcomes are critical for continued supply to regulated markets.

• Quality Specifications:

  • Assay: Typically required to be between 98.0% and 102.0% of Acamprosate Calcium on an anhydrous basis.
  • Impurities: Strict limits are set for related substances, residual solvents, and heavy metals. Specific impurity profiles are detailed in DMFs and pharmacopeial monographs.
  • Water Content: Controlled within a specified range, often determined by Karl Fischer titration.
  • Particle Size Distribution: Important for formulation development, especially for solid dosage forms.

Which API Suppliers Have a Strong Track Record in Regulated Markets?

Suppliers with a history of successful regulatory inspections and DMF submissions to agencies like the FDA and EMA are considered strong contenders for supplying Acamprosate Calcium API to developed markets.

• Proven Suppliers in Regulated Markets:
  • Strides Pharma Science Limited: Holds multiple DMFs for its APIs, including in regulated markets.
  • Laurus Labs Limited: Actively files DMFs with the FDA and maintains a strong compliance record.
  • Alkem Laboratories Ltd.: Has a significant presence in regulated markets with a history of successful FDA inspections.
  • Divi's Laboratories Limited: A well-established supplier to global pharmaceutical companies, recognized for its quality and compliance.
  • Sun Pharmaceutical Industries Ltd.: Possesses extensive regulatory experience and a broad portfolio of approved APIs for international markets.
  • Zydus Lifesciences Limited: Engages in global regulatory filings and adheres to international quality standards.

These companies invest heavily in quality control systems, analytical method validation, and regulatory affairs departments to ensure their APIs meet the highest standards required by pharmaceutical companies marketing products in the U.S., Europe, Japan, and other highly regulated countries.

What is the Competitive Landscape and Potential for New Entrants?

The Acamprosate Calcium API market is characterized by a mature competitive landscape dominated by established players, particularly from India. Entry for new manufacturers presents significant hurdles related to capital investment, regulatory compliance, and establishing market trust.

• Market Dynamics:

  • Price Sensitivity: While quality is paramount, pricing remains a competitive factor, especially for generic drug manufacturers.
  • Intellectual Property: While the primary patents for Acamprosate Calcium have long expired, process patents or polymorph patents could still be relevant in specific jurisdictions. A thorough IP landscape analysis is crucial for new entrants.
  • Customer Relationships: Long-standing relationships between API manufacturers and major generic drug companies are difficult to displace.

• Barriers to Entry:

  • Regulatory Hurdles: Achieving FDA, EMA, and other regulatory body approvals for manufacturing facilities and APIs is a time-consuming and expensive process.
  • Capital Investment: Establishing state-of-the-art cGMP-compliant manufacturing facilities requires substantial financial outlay.
  • Technical Expertise: Developing and validating robust, scalable, and cost-effective synthesis routes for Acamprosate Calcium demands specialized chemical engineering and pharmaceutical science expertise.
  • Quality Assurance Infrastructure: Implementing and maintaining a comprehensive quality management system that meets global regulatory expectations is critical.

New entrants would likely focus on niche markets, specialized formulations, or innovative manufacturing processes to gain traction. Demonstrating superior impurity profiles or unique physical characteristics of the API could also provide a competitive edge.

What are the Typical Lead Times and Pricing Structures for Acamprosate Calcium API?

Lead times and pricing for Acamprosate Calcium API are influenced by supplier capacity, order volume, geographic location, and current market demand.

• Lead Time Factors:

  • Standard Production Cycles: Manufacturers typically operate on production cycles that can range from several weeks to a few months, depending on batch size and production schedules.
  • Inventory Levels: Suppliers maintain varying levels of safety stock. Immediate availability is rare for large volumes.
  • Regulatory Approvals: For new customers or new product lines, initial lead times can be longer due to required site audits and documentation reviews.
  • Shipping and Customs: Transit time from manufacturing sites (primarily India and China) to global destinations can add 2-4 weeks.

• Pricing Structure Considerations:

  • Volume Discounts: Pricing is highly dependent on the quantity ordered. Larger, multi-ton orders command lower per-kilogram prices.
  • Contractual Agreements: Long-term supply agreements often include negotiated pricing, providing stability for both the supplier and the buyer.
  • Cost of Raw Materials: Fluctuations in the cost of key starting materials and intermediates directly impact API pricing.
  • Regulatory Compliance Costs: The investment in maintaining GMP compliance, filing DMFs, and undergoing inspections is factored into API costs.
  • Market Demand: Periods of high demand can lead to price increases, while oversupply can exert downward pressure on prices.
  • Estimated Price Range: While highly variable, bulk Acamprosate Calcium API pricing can range from approximately $80 to $250 per kilogram, depending on the factors above.

Formulators and generic manufacturers typically engage in direct negotiations with API suppliers to secure favorable pricing and supply terms.

Key Takeaways

• The global supply of Acamprosate Calcium API is concentrated in India and China, with established players like Strides Pharma Science, Laurus Labs, Alkem Laboratories, Divi's Laboratories, Sun Pharmaceutical Industries, Zydus Lifesciences, and Jiangsu Hengdian Group Biomedical being prominent manufacturers.
• Suppliers must meet stringent regulatory requirements, including cGMP compliance, and possess approved DMFs or ASMFs for regulated markets.
• The competitive landscape is mature, with significant barriers to entry for new manufacturers due to regulatory hurdles, capital investment, and established customer relationships.
• Lead times for API procurement can range from several weeks to months, influenced by production cycles, inventory, and logistics.
• Pricing is volume-dependent and subject to market dynamics, raw material costs, and regulatory compliance expenses, with estimated ranges from $80 to $250 per kilogram.

Frequently Asked Questions

1. What is the primary quality standard for Acamprosate Calcium API used in pharmaceutical formulations? Acamprosate Calcium API must conform to the specifications outlined in major pharmacopeias, most notably the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.). These monographs detail purity limits, impurity profiles, assay requirements, and physical characteristics.

2. How do regulatory inspections by agencies like the FDA impact API supplier selection? Successful and recent regulatory inspections by the FDA, EMA, or other comparable health authorities are critical. They validate a supplier's adherence to cGMP, demonstrating their ability to consistently produce high-quality API. A history of regulatory non-compliance or import alerts can disqualify a supplier.

3. Can Anspec Company, Inc. be considered a direct manufacturer of Acamprosate Calcium API, or are they a distributor? Anspec Company, Inc. primarily functions as a distributor and custom synthesis provider, sourcing Acamprosate Calcium API from global manufacturers. While they may perform final quality control or repackaging, they are not typically the primary bulk synthesis manufacturer for this API.

4. What are the implications of relying on a single supplier for Acamprosate Calcium API? Relying on a single supplier introduces supply chain risk. Disruptions due to unforeseen events such as manufacturing issues, regulatory actions, natural disasters, or geopolitical instability can halt production. Diversifying suppliers, where feasible, mitigates these risks.

5. Are there specific impurity concerns unique to Acamprosate Calcium API that formulators should monitor closely? Yes, as with any API, specific process-related impurities and degradation products must be identified and controlled. Manufacturers' DMFs will detail the impurity profile and the methods used for their detection and quantification. Formulators must ensure that their chosen API supplier meets the stringent impurity limits specified in pharmacopeial monographs and regulatory filings to ensure product safety and efficacy.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from [FDA Website - specific page not provided, general information on DMFs] [2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability (CEP). Retrieved from [EDQM Website - specific page not provided, general information on CEPs] [3] United States Pharmacopeia. (n.d.). USP General Chapters and Monographs. Retrieved from [USP Website - specific page not provided, general information on pharmacopeial standards] [4] European Pharmacopoeia. (n.d.). Ph. Eur. General Chapters and Monographs. Retrieved from [EDQM Website - specific page not provided, general information on pharmacopeial standards]